Quick Answer
Aquestive Therapeutics, Inc. reported Research And Development Expense of $17.19 million for the year ending 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -15.2% in Research And Development Expense from 2024 to 2025.
- This data is from Aquestive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $4.84 million | Q3 2017: $5.68 million | Q1 2018: $4.90 million | Q2 2018: $7.99 million | Q3 2018: $4.53 million | Q1 2019: $4.30 million | Q2 2019: $8.15 million | Q3 2019: $5.06 million | Q1 2020: $4.35 million | Q2 2020: $3.85 million | Q3 2020: $7.26 million | Q1 2021: $3.66 million | Q2 2021: $4.26 million | Q3 2021: $4.73 million | Q1 2022: $4.77 million | Q2 2022: $5.20 million | Q3 2022: $3.23 million | Q1 2023: $3.55 million | Q2 2023: $3.47 million | Q3 2023: $3.20 million | Q1 2024: $5.93 million | Q2 2024: $4.16 million | Q3 2024: $5.27 million | Q1 2025: $5.36 million | Q2 2025: $4.11 million | Q3 2025: $4.53 million.
- Over the full 9 years of available data (2017 to 2025), Aquestive Therapeutics, Inc.'s Research And Development Expense has declined by 22.3%.
- Historical annual values: Fiscal year 2025: $17.19 million | Fiscal year 2024: $20.28 million | Fiscal year 2023: $13.10 million | Fiscal year 2022: $17.48 million | Fiscal year 2021: $17.05 million | Fiscal year 2020: $19.89 million | Fiscal year 2019: $20.57 million | Fiscal year 2018: $23.11 million | Fiscal year 2017: $22.13 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: